4D Molecular Therapeutics (FDMT)

• Market cap: $155M
• 1 day: 2.77%
• 5 days: 10.60%
• 1 month: -9.73%
• 3 months: -29.24%
• 6 months: -59.02%
• Year to date: -42.71%
• 1 year: -85.81%
• 5 years: -91.75%
• 10 years: -91.75%
• Sector: Healthcare
• Industry: Biotechnology

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 227

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

132% more call options, than puts

Call options by funds: $858K | Put options by funds: $370K

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

16% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 44

4% more funds holding

Funds holding: 139 [Q3] → 144 (+5) [Q4]

9.68% less ownership

Funds ownership: 111.05% [Q3] → 101.37% (-9.68%) [Q4]

58% less capital invested

Capital invested by funds: $625M [Q3] → $262M (-$363M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 738% upside
• Avg. target: $35 940% upside
• High target: $40 1,098% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Tazeen Ahmad 25% 1-year accuracy 8 / 32 met price target	1,098% upside $40	Buy Maintained	10 Mar 2025
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 59 met price target	738% upside $28	Buy Maintained	4 Mar 2025
RBC Capital Luca Issi 17% 1-year accuracy 9 / 54 met price target	948% upside $35	Outperform Maintained	3 Mar 2025
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 69 met price target	978% upside $36	Buy Reiterated	3 Mar 2025